Bakkach Joaira, Mansouri Mohamed, Derkaoui Touria, Loudiyi Ali, Fihri Mohamed, Hassani Samia, Barakat Amina, Ghailani Nourouti Naima, Bennani Mechita Mohcine
Human Genomic Research Laboratory, Faculty of Sciences and Techniques of Tangier, University Abdelmalek Essaâdi, Tangier, Morocco.
Oncology Clinic AL AMAL of Tangier, Tangier, Morocco.
BMC Womens Health. 2017 Nov 9;17(1):106. doi: 10.1186/s12905-017-0456-1.
Literature data reported a higher frequency of breast cancer in young women (BCYW) in developing countries. BCYW is associated with delayed diagnosis, aggressive biology and poor prognosis. However, our knowledge of biological profile, treatment received and outcome of young patients is still limited in Morocco. We propose to analyze clinicopathologic, therapeutic and prognostic features of BCYW among a series of patients native and/or inhabitant of North of Morocco.
We carried out a retro-prospective study of 331 infiltrating breast cancer cases registered between January 2010 and December 2015. Details of tumor pathology, treatment and outcome were collected. Disease-Free Survival (DFS) and Overall Survival (OS) were assessed by Kaplan-Meier analysis.
A total of 82 patients were diagnosed with breast cancer at the age of 40 or younger (24.8%). Median age was 36 years. More than one quarter (26%) of patients had family history of breast or ovarian cancer. Advanced stages accounted for 34.2% of cases. Median tumor diameter was 2.8 cm. Intermediate and high-grade tumors represented 47.6% and 40.2%, respectively. Nodal involvement was present in 58.5% and lymphovascular invasion was found in 47.7% of the patients. About two thirds (66.2%) of tumors were hormone receptor positive, 29.2% over-expressed HER2 receptor and 23% were triple negative. Patients underwent breast conserving surgery in 38.2% of cases, 61.7% were offered adjuvant chemotherapy and 84.6% received hormone therapy. Five-year DFS and OS were respectively 88.9% and 75.6%. Locoregional recurrence occurred in 2.8% of cases and 8.3% of patients developed distant metastases.
Our findings are in accordance with previous studies that have shown a higher frequency of breast cancer among Moroccan young women. In line with literature data, clinicopathologic profile seems to be aggressive and prognosis is pejorative in our series.
文献数据显示,发展中国家年轻女性乳腺癌(BCYW)的发病率较高。BCYW与诊断延迟、生物学行为侵袭性强及预后不良有关。然而,在摩洛哥,我们对年轻患者的生物学特征、接受的治疗及预后的了解仍然有限。我们建议分析摩洛哥北部一系列本地和/或居住患者中BCYW的临床病理、治疗及预后特征。
我们对2010年1月至2015年12月登记的331例浸润性乳腺癌病例进行了回顾性前瞻性研究。收集了肿瘤病理、治疗及预后的详细信息。采用Kaplan-Meier分析评估无病生存期(DFS)和总生存期(OS)。
共有82例患者在40岁及以下被诊断为乳腺癌(24.8%)。中位年龄为36岁。超过四分之一(26%)的患者有乳腺癌或卵巢癌家族史。晚期病例占34.2%。肿瘤中位直径为2.8 cm。中级别和高级别肿瘤分别占47.6%和40.2%。58.5%的患者有淋巴结受累,47.7%的患者有淋巴管浸润。约三分之二(66.2%)的肿瘤激素受体阳性,29.2%的肿瘤HER2受体过表达,23%为三阴性。38.2%的病例接受了保乳手术,61.7%的患者接受了辅助化疗,84.6%的患者接受了激素治疗。五年DFS和OS分别为88.9%和75.6%。2.8%的病例发生局部区域复发,8.3%的患者发生远处转移。
我们的研究结果与先前的研究一致,即摩洛哥年轻女性乳腺癌的发病率较高。与文献数据一致,在我们的系列研究中,临床病理特征似乎具有侵袭性,预后较差。